Most pharma “social listening” reports are sentiment dashboards. They tell you whether the internet feels vaguely positive. They almost never give you a named unmet need, in a specific indication, with the actual words a patient or HCP used.
IndicationIQ is built for that gap. It surfaces patient unmet needs and HCP signals from public conversation, and every finding is backed by a quote. If you cannot point to the sentence, it does not belong in a brand plan.
Why generic listening tools miss the work
Brand teams do not need another word cloud. They need answers to questions like:
- What are patients actually struggling with after diagnosis, during titration, at the end of a cycle?
- Which side-effects are discussed as deal-breakers versus background noise?
- What are HCPs saying in public that never makes it into an advisory board?
- Which needs are already owned by a competitor’s narrative?
Those questions require extraction, not averages. Sentiment is a summary statistic. Unmet-need research is a list of claims you can take to medical, market access, or a creative brief — with evidence attached.
The method is written up in How I track patient unmet needs from public conversation.
Who it is for
- Brand teams who cannot justify an enterprise listening suite for one indication
- Insights and competitive-intelligence leads who need quote-backed findings
- Medical and HEOR colleagues who will not accept a theme without a source
IndicationIQ currently sits under Matt Powell T/A Elliogen, and is likely to become its own company as it grows.